相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics
Daniela Bumbaca et al.
AAPS JOURNAL (2012)
Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
Rong Deng et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Hepatitis C virus entry: beyond receptors
Luke W. Meredith et al.
REVIEWS IN MEDICAL VIROLOGY (2012)
Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies Retrospective Analysis of Monkey as a Single Species for First-in-Human Prediction
Jennifer Q. Dong et al.
CLINICAL PHARMACOKINETICS (2011)
A genetically humanized mouse model for hepatitis C virus infection
Marcus Dorner et al.
NATURE (2011)
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
Mohammad Tabrizi et al.
AAPS JOURNAL (2010)
Impact of Molecular Processing in the Hinge Region of Therapeutic IgG4 Antibodies on Disposition Profiles in Cynomolgus Monkeys
Kay Stubenrauch et al.
DRUG METABOLISM AND DISPOSITION (2010)
Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations
Hans Peter Grimm
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2009)
The global burden of hepatitis C
Daniel Lavanchy
LIVER INTERNATIONAL (2009)
Development and Evaluation of a FACS-Based Medium-Throughput Assay for HCV Entry Inhibitors
Sigrid Ziegler et al.
JOURNAL OF BIOMOLECULAR SCREENING (2009)
Anti-CD81 Antibodies Can Prevent a Hepatitis C Virus Infection In Vivo
Philip Meuleman et al.
HEPATOLOGY (2008)
Tissue distribution of humanized anti-human Fas monoclonal antibody (R-125224) based on fas antigen-antibody reaction in collagen-induced arthritis monkeys
Motoko Saito et al.
LIFE SCIENCES (2007)
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry
Matthew J. Evans et al.
NATURE (2007)
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data:: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver
Zoe E. Barter et al.
CURRENT DRUG METABOLISM (2007)
Elimination mechanisms of therapeutic monoclonal antibodies
MA Tabrizi et al.
DRUG DISCOVERY TODAY (2006)
Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers
CM Ng et al.
PHARMACEUTICAL RESEARCH (2006)
Complete replication of hepatitis C virus in cell culture
BD Lindenbach et al.
SCIENCE (2005)
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome
T Wakita et al.
NATURE MEDICINE (2005)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes
B Bartosch et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
IMGT, the international ImMunoGeneTics database (R)
MP Lefranc
NUCLEIC ACIDS RESEARCH (2003)
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus
E Scarselli et al.
EMBO JOURNAL (2002)
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition
DE Mager et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs
K Kitadokoro et al.
EMBO JOURNAL (2001)
分享论文
